Evidence map›Paper›PMID 42662057›Full record

ArticleESMO gastrointestinal oncology2026

A multicenter pilot study of nivolumab with drug-eluting bead transarterial chemoembolization in patients with liver-limited hepatocellular carcinoma.

J J Harding, O M Fitzpatrick, J F Chou, H Yarmohammadi, K A Reiss, R K Do, P Wong, D N Khalil, I El Dika, C Ferrer and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

J J HardingDepartment of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
O M FitzpatrickDepartment of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
J F ChouDepartment of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
H YarmohammadiDepartment of Radiology, Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
K A ReissDivision of Hematology-Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
R K DoDepartment of Radiology, Weill Cornell Medical College, New York, New York, USA.
P WongImmune Monitoring Core Facility, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
D N KhalilDepartment of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
I El DikaDepartment of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
C FerrerDepartment of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
O HeffernanDepartment of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
A YaqubieDepartment of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
J D GiardinaMallinckrodt Institute of Radiology, Siteman Cancer Center, Washington University, St. Louis, Missouri, USA.
M D'AngelicaDepartment of Surgery, Hepatopancreatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
W R JarnaginDepartment of Surgery, Hepatopancreatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
G NadolskiDivision of Interventional Radiology, Department of Radiology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
A CoveyDepartment of Radiology, Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
J P ErinjeriDepartment of Radiology, Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
K BrownDepartment of Radiology, Interventional Radiology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
M C SoulenDivision of Interventional Radiology, Department of Radiology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
B TanDivision of Oncology, Department of Medicine, Siteman Cancer Center, Washington University, St. Louis, Missouri, USA.
M CapanuDepartment of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
G K Abou-AlfaDepartment of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)U01CA238444 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CERCEK, ANDREA, IACOBUZIO-DONAHUE, CHRISTINE A · 2020 to 2024
$3.3M
NCI NIH HHS P30 CA008748NCI NIH HHS U01 CA238444
6 · The paper itself

Abstract

Background: Drug-eluting bead transarterial chemoembolization (deb-TACE) is a standard for liver-limited, locally advanced hepatocellular carcinoma (HCC) and may enhance response to immune checkpoint inhibition through tumor immune microenvironment modulation. We evaluated nivolumab combined with deb-TACE. Patients and methods: This phase I, multicenter trial used a 3 + 3 design with expansion, evaluating three nivolumab schedules relative to deb-TACE. Eligible patients had unresectable, liver-limited HCC. Patients underwent deb-TACE and received nivolumab 240 mg i.v. every 2 weeks for up to 1 year, according to cohort-specific schedules. The primary outcome was safety. Secondary outcomes included objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Exploratory immune outcomes included peripheral T-cell subsets and cytokines. Results: Nineteen patients were treated. One dose-limiting toxicity (grade 3 transaminitis) resolved without intervention and did not recur with rechallenge. Common treatment-related adverse events were fatigue (53%), transaminase elevation (42%), and fever (37%). The ORR was 21% [95% confidence interval (CI) 6% to 44%]. With a median follow-up time of 72.7 months, median PFS and OS were 5.9 months (95% CI 3.6-23) and 23 months (95% CI 19-62), respectively. Transient immune changes occurred but were not statistically significant and without persistent effects. Conclusion: Nivolumab combined with deb-TACE demonstrated acceptable tolerability across dosing schedules but did not enhance antitumor activity beyond historical benchmarks for deb-TACE alone. In the context of recent phase III trials that have yet to demonstrate an overall survival benefit for TACE plus immune checkpoint inhibitor combinations, these findings underscore the need for hypothesis-driven trial designs incorporating improved patient selection criteria and rational combinatorial strategies.

Indexed as

chemoembolizationcombinationhepatocellular carcinomaimmunotherapysafety

Identifiers

PMID42662057
PMCPMC13519073

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.